Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD

Current share price for RAD : $0.010 -0.011 (-52.38%)⁺

Announcement

Quarterly Activities/Appendix 4C Cash Flow Report

Release

23 Apr 2026 9:04AM

Price at Release

$0.021

Full Release

Summary

Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company, reported its activities and financials for the quarter ending 31 March 2026. The company made significant progress in its clinical trials, notably completing enrolment in a Phase 2b trial of RAD 101 and advancing RAD 202 to a higher dose level due to positive interim data. Two new First-In-Human trials were initiated for their radiotherapeutic products. Financially, the company ended the quarter with $19.2 million in cash, experiencing a significant cash outflow mainly due to research and development and staffing costs. Radiopharm anticipates raising further capital through equity and expects a substantial R&D tax incentive soon.

Key Points

Radiopharm Theranostics Limited reported on their quarterly activities and cash flow for the quarter ending 31 March 2026.
The company completed enrolment in a Phase 2b clinical trial for RAD 101, showing 90% concordance with MRI in patients with recurrent brain metastases.
Interim data for RAD 202 demonstrated favorable safety and tumor uptake, and the company received approval to advance to the next dose level.
Radiopharm initiated two First-In-Human clinical trials for radiotherapeutic assets RV-01 and RAD 402.
The company's cash and cash equivalents at the end of the quarter were $19.2 million, down from $34.5 million at the beginning of the quarter.
Net cash outflow from operating activities was $14.9 million, largely due to R&D expenses and staff costs.
Directors believe they can raise additional capital through equity financing and expect to receive a significant R&D Tax Incentive.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.